Bacteriology, antibiotic resistance and risk stratification of patients with culture-positive, community-acquired pleural infection.

Background: Community-acquired pleural infection (CAPI) is a growing health problem worldwide. Although most CAPI patients recover with antibiotics and pleural drainage, 20% require surgical intervention. The use of inappropriate antibiotics is a common cause of treatment failure.

Unravelling the Features of Success of VIM-Producing ST111 and ST235 in a Greek Hospital.

The objective of this study was to analyze the characteristics that contribute to the successful dissemination of VIM-producing (), belonging to ST111 and ST235, in a Greek hospital. A total of 120 non-repetitive , which had meropenem minimal inhibitory concentrations (MICs) greater than 2 mg/L, were studied. VIM-encoding genes were amplified and sequenced within their integrons.

Implementation of the Rapid Polymyxin™ NP test directly to positive blood cultures bottles.

The present study assessed the performance of Rapid Polymyxin™ NP test to detect colistin resistance directly from 132 blood cultures found positive for Enterobacterales by FilmArray. Additionally, colistin MICs of isolated microorganisms were determined by the commercial broth microdilution method ComASP™ Colistin, used as the gold standard comparator. The Rapid Polymyxin™ NP test correctly detected all colistin-resistant isolates.

Evaluation of rapid polymyxin NP test to detect colistin-resistant Klebsiella pneumoniae isolated in a tertiary Greek hospital.

The efficiency of Rapid Polymyxin NP test for detection of colistin-resistant isolates was tested against a collection of 131 non-repetitive Klebsiella pneumoniae, including 98 colistin-resistant and 33 colistin-susceptible isolates. In addition, the performance of this test was compared with those of the automated systems, BD Phoenix™ and VITEK®2, and the Etest. Determination of imipenem and meropenem MICs showed that 95 of colistin-resistant (Col-R) isolates were also resistant to at least one carbapenem.

Nebulised colistin for ventilator-associated pneumonia prevention.

We evaluated whether prophylactic nebulised colistin could reduce ventilator-associated pneumonia (VAP) rates in an intensive care unit (ICU) setting with prevalent multidrug-resistant (MDR) bacteria.We used a single-centre, two-arm, randomised, open-label, controlled trial in a 12-bed ICU in the University Hospital of Larissa, Greece. Patient inclusion criteria included mechanical ventilation of >48 h.